Clinical Trials
2 trialsNCT07377578 2026-02-06
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3 Recruiting
NCT06082102 2025-09-15
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Recruiting